Literature DB >> 22157363

An overview of cholera vaccines and their public health implications.

Sachin N Desai1, John D Clemens.   

Abstract

PURPOSE OF REVIEW: The current cholera pandemic now involves almost the entire developing world and represents an important global challenge. Though improved water and sanitation remain the mainstays of cholera prevention efforts, major improvements to infrastructure continue to be a goal far out of reach for many of those affected and near-term interventions, including vaccines, need consideration. RECENT
FINDINGS: Prolonged and frequent epidemics, increased antimicrobial resistance, and heightening awareness of the role of climate change in disease burden have returned cholera to the forefront of the international public health forum. The availability of new oral cholera vaccines and supporting data have prompted the WHO to recommend vaccination be used with other prevention and control strategies where disease is endemic, and their use should be considered in outbreak situations.
SUMMARY: Vibrio cholerae, a highly transmissible organism, is found in aquatic reservoirs and is not an eradicable disease. New variant strains appear to cause more severe clinical disease, and may be displacing earlier seventh pandemic organisms as the major cause of cholera. Licensed newer-generation oral vaccines have proven to be well tolerated, protective (including against new variant strains), and affordable and offer a new tool to control cholera.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22157363     DOI: 10.1097/MOP.0b013e32834eb625

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  9 in total

1.  Sociocultural determinants of anticipated vaccine acceptance for acute watery diarrhea in early childhood in Katanga Province, Democratic Republic of Congo.

Authors:  Sonja Merten; Christian Schaetti; Cele Manianga; Bruno Lapika; Raymond Hutubessy; Claire-Lise Chaignat; Mitchell Weiss
Journal:  Am J Trop Med Hyg       Date:  2013-07-22       Impact factor: 2.345

2.  Safety of oral cholera vaccines during pregnancy in developing countries.

Authors:  Ashraful Islam Khan; Md Taufiqul Islam; Firdausi Qadri
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

3.  Cholera vaccination: pregnant women excluded no more.

Authors:  Pedro L Moro; Lakshmi Sukumaran
Journal:  Lancet Infect Dis       Date:  2017-02-02       Impact factor: 25.071

4.  Lipopolysaccharide modifications of a cholera vaccine candidate based on outer membrane vesicles reduce endotoxicity and reveal the major protective antigen.

Authors:  Deborah R Leitner; Sandra Feichter; Kristina Schild-Prüfert; Gerald N Rechberger; Joachim Reidl; Stefan Schild
Journal:  Infect Immun       Date:  2013-04-29       Impact factor: 3.441

5.  Development of pVCR94ΔX from Vibrio cholerae, a prototype for studying multidrug resistant IncA/C conjugative plasmids.

Authors:  Nicolas Carraro; Maxime Sauvé; Dominick Matteau; Guillaume Lauzon; Sébastien Rodrigue; Vincent Burrus
Journal:  Front Microbiol       Date:  2014-02-06       Impact factor: 5.640

6.  N-glycosylation of cholera toxin B subunit in Nicotiana benthamiana: impacts on host stress response, production yield and vaccine potential.

Authors:  Krystal Teasley Hamorsky; J Calvin Kouokam; Jessica M Jurkiewicz; Bailey Nelson; Lauren J Moore; Adam S Husk; Hiroyuki Kajiura; Kazuhito Fujiyama; Nobuyuki Matoba
Journal:  Sci Rep       Date:  2015-01-23       Impact factor: 4.379

7.  Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro.

Authors:  Kavita R Manhas; Pamela A Marshall; Carl E Wagner; Peter W Jurutka; Michelle V Mancenido; Hannah Z Debray; Joseph N Blattman
Journal:  Front Immunol       Date:  2022-01-27       Impact factor: 7.561

8.  Predictors of disease severity in patients admitted to a cholera treatment center in urban Haiti.

Authors:  Claude-Lyne Valcin; Karine Severe; Claudia T Riche; Benedict S Anglade; Colette Guiteau Moise; Michael Woodworth; Macarthur Charles; Zhongze Li; Patrice Joseph; Jean W Pape; Peter F Wright
Journal:  Am J Trop Med Hyg       Date:  2013-10       Impact factor: 2.345

9.  Feasibility and costs of a targeted cholera vaccination campaign in Ethiopia.

Authors:  Samuel Teshome; Sachin Desai; Jerome H Kim; Dires Belay; Vittal Mogasale
Journal:  Hum Vaccin Immunother       Date:  2018-05-10       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.